MX2012002114A - Vacuna de paramixovirus aviar recombinante y metodo para hacerla y usarla. - Google Patents
Vacuna de paramixovirus aviar recombinante y metodo para hacerla y usarla.Info
- Publication number
- MX2012002114A MX2012002114A MX2012002114A MX2012002114A MX2012002114A MX 2012002114 A MX2012002114 A MX 2012002114A MX 2012002114 A MX2012002114 A MX 2012002114A MX 2012002114 A MX2012002114 A MX 2012002114A MX 2012002114 A MX2012002114 A MX 2012002114A
- Authority
- MX
- Mexico
- Prior art keywords
- apmv
- methods
- vaccine
- methylbenzoic acid
- recombinant
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 8
- 229960005486 vaccine Drugs 0.000 title abstract 7
- 241000271566 Aves Species 0.000 title 1
- 241000724287 Apple mosaic virus Species 0.000 abstract 12
- 239000000203 mixture Substances 0.000 abstract 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 4
- GPSDUZXPYCFOSQ-UHFFFAOYSA-N m-toluic acid Chemical compound CC1=CC=CC(C(O)=O)=C1 GPSDUZXPYCFOSQ-UHFFFAOYSA-N 0.000 abstract 4
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 abstract 4
- LPNBBFKOUUSUDB-UHFFFAOYSA-N p-toluic acid Chemical compound CC1=CC=C(C(O)=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-N 0.000 abstract 4
- 239000006185 dispersion Substances 0.000 abstract 3
- 239000005711 Benzoic acid Substances 0.000 abstract 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 abstract 2
- 235000010233 benzoic acid Nutrition 0.000 abstract 2
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 abstract 2
- 239000007791 liquid phase Substances 0.000 abstract 2
- 239000007800 oxidant agent Substances 0.000 abstract 2
- 230000001590 oxidative effect Effects 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 239000003054 catalyst Substances 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/68—Stabilisation of the vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18141—Use of virus, viral particle or viral elements as a vector
- C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18151—Methods of production or purification of viral material
- C12N2760/18152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2999/00—Further aspects of viruses or vectors not covered by groups C12N2710/00 - C12N2796/00 or C12N2800/00
- C12N2999/007—Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Crystallography & Structural Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23591209P | 2009-08-21 | 2009-08-21 | |
| PCT/US2010/046179 WO2011022656A2 (en) | 2009-08-21 | 2010-08-20 | Recombinant avian paramyxovirus vaccine and method for making and using thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012002114A true MX2012002114A (es) | 2012-08-08 |
Family
ID=43027613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002114A MX2012002114A (es) | 2009-08-21 | 2010-08-20 | Vacuna de paramixovirus aviar recombinante y metodo para hacerla y usarla. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8486418B2 (enExample) |
| EP (2) | EP3210622B1 (enExample) |
| JP (2) | JP6221167B2 (enExample) |
| KR (1) | KR101745029B1 (enExample) |
| CN (2) | CN102573901B (enExample) |
| BR (1) | BR112012003837B8 (enExample) |
| CA (1) | CA2771540C (enExample) |
| CL (2) | CL2012000447A1 (enExample) |
| CO (1) | CO6511253A2 (enExample) |
| ES (2) | ES2622087T3 (enExample) |
| HU (2) | HUE053237T2 (enExample) |
| MX (1) | MX2012002114A (enExample) |
| PL (2) | PL3210622T3 (enExample) |
| PT (2) | PT2467158T (enExample) |
| RU (2) | RU2592544C2 (enExample) |
| SG (2) | SG178523A1 (enExample) |
| UA (1) | UA110328C2 (enExample) |
| WO (1) | WO2011022656A2 (enExample) |
| ZA (1) | ZA201201245B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014158811A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
| US20140341950A1 (en) * | 2013-05-15 | 2014-11-20 | University Of Georgia Research Foundation, Inc. | Recombinant avian paramyxovirus vaccine and method for making and using thereof |
| SG11201607130RA (en) | 2014-02-27 | 2016-09-29 | Viralytics Ltd | Combination method for treatment of cancer |
| CN104195116B (zh) * | 2014-08-13 | 2018-03-06 | 吉林大学 | 一种表达鹅细小病毒vp3基因的重组新城疫病毒及其构建方法 |
| WO2016027135A1 (es) * | 2014-08-22 | 2016-02-25 | Idisa Innovacion, S.A. De C.V. | VACUNA EMULSIONADA PARA OBTENER FORMULACIONES DE INMUNOGLOBULINAS IgY CONCENTRADAS; PROCESOS Y USOS DE LAS MISMAS. |
| CA2966191A1 (en) | 2014-11-03 | 2016-05-12 | Merial, Inc. | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| CN107254450A (zh) * | 2017-07-20 | 2017-10-17 | 扬州大学 | 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法 |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| CN108315486A (zh) * | 2018-04-11 | 2018-07-24 | 张薇 | 一种用于检测罗湖病毒的环介导等温扩增引物组及试剂盒 |
| WO2020014591A1 (en) * | 2018-07-13 | 2020-01-16 | Icahn School Of Medicine At Mount Sinai | Apmv and uses thereof for the treatment of cancer |
| US12391957B2 (en) | 2018-08-17 | 2025-08-19 | Icahn School Of Medicine At Mount Sinai | Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease |
| MX2021010075A (es) | 2019-02-20 | 2021-12-10 | Modernatx Inc | Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales. |
| CN114390946A (zh) | 2019-11-13 | 2022-04-22 | 株式会社Ihi | 将填充部件插入反应装置中的夹具 |
| CN112111467B (zh) * | 2020-09-27 | 2021-06-22 | 湖北省农业科学院畜牧兽医研究所 | 一种基因vii型新城疫标记疫苗株及其制备方法与应用 |
| CN116068196A (zh) * | 2022-10-26 | 2023-05-05 | 新疆农业大学 | 一种检测禽副黏病毒4型血清抗体的elisa方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
| WO1992015672A1 (en) | 1991-03-07 | 1992-09-17 | Virogenetics Corporation | Genetically engineered vaccine strain |
| ES2241042T3 (es) | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora. |
| FR2778858B1 (fr) | 1998-05-20 | 2000-06-16 | Oreal | Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique |
| EP0974660A1 (en) * | 1998-06-19 | 2000-01-26 | Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) | Newcastle disease virus infectious clones, vaccines and diagnostic assays |
| FR2801607B1 (fr) | 1999-11-26 | 2001-12-28 | Merial Sas | Pneumovirus du canard et vaccins correspondants |
| RU2162341C1 (ru) * | 2000-03-06 | 2001-01-27 | Открытое акционерное общество "ВЫМПЕЛ КОМПЛЕКС" | Сухая живая вакцина против ньюкаслской болезни и способ ее получения |
| JP4791651B2 (ja) * | 2000-05-18 | 2011-10-12 | 株式会社ディナベック研究所 | 外来遺伝子導入用パラミクソウイルスベクター |
| ATE352557T1 (de) * | 2000-11-02 | 2007-02-15 | Intervet Int Bv | Rekombinantes nukleoprotein von newcastle- krankheitsvirus als markierungsimpfstoff |
| EP1651265B1 (en) | 2003-07-24 | 2008-04-23 | Merial Limited | Vaccine formulations comprising an oil-in-water emulsion |
| KR20090007706A (ko) | 2006-03-15 | 2009-01-20 | 인터벳 인터내셔널 비.브이. | 조류 인플루엔자 바이러스의 ｈ5 헤마글루티닌을 발현하는 재조합 뉴캐슬병 바이러스 |
| RU2441070C2 (ru) * | 2006-03-15 | 2012-01-27 | Интервет Интернэшнл Б.В. | Рекомбинантный вирус болезни ньюкастла, экспрессирующий н5 гемаглютинин вируса птичьего гриппа (avian ineluenza) |
| EP1834651A1 (en) * | 2006-03-15 | 2007-09-19 | Universiteit Gent | Compositions and methods for veterinary vaccination |
| US20090175826A1 (en) * | 2006-06-05 | 2009-07-09 | Elankumaran Subbiah | Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same |
| US20090208495A1 (en) | 2008-02-14 | 2009-08-20 | Bayer Schering Pharma Ag | Anti-tumor effective paramyxovirus |
| CN102428099B (zh) * | 2009-04-03 | 2016-03-16 | 梅里亚有限公司 | 运载新城疫病毒的禽疫苗 |
-
2010
- 2010-08-20 MX MX2012002114A patent/MX2012002114A/es active IP Right Grant
- 2010-08-20 SG SG2012011912A patent/SG178523A1/en unknown
- 2010-08-20 PT PT107471336T patent/PT2467158T/pt unknown
- 2010-08-20 PL PL16204538T patent/PL3210622T3/pl unknown
- 2010-08-20 PL PL10747133T patent/PL2467158T3/pl unknown
- 2010-08-20 KR KR1020127007373A patent/KR101745029B1/ko active Active
- 2010-08-20 US US12/860,589 patent/US8486418B2/en active Active
- 2010-08-20 BR BR112012003837A patent/BR112012003837B8/pt active Search and Examination
- 2010-08-20 RU RU2012110576/10A patent/RU2592544C2/ru active
- 2010-08-20 CN CN201080045564.7A patent/CN102573901B/zh active Active
- 2010-08-20 EP EP16204538.9A patent/EP3210622B1/en active Active
- 2010-08-20 UA UAA201203242A patent/UA110328C2/ru unknown
- 2010-08-20 ES ES10747133T patent/ES2622087T3/es active Active
- 2010-08-20 RU RU2016112465A patent/RU2016112465A/ru not_active Application Discontinuation
- 2010-08-20 ES ES16204538T patent/ES2867457T3/es active Active
- 2010-08-20 HU HUE16204538A patent/HUE053237T2/hu unknown
- 2010-08-20 WO PCT/US2010/046179 patent/WO2011022656A2/en not_active Ceased
- 2010-08-20 HU HUE10747133A patent/HUE033886T2/en unknown
- 2010-08-20 JP JP2012525730A patent/JP6221167B2/ja active Active
- 2010-08-20 SG SG10201405123WA patent/SG10201405123WA/en unknown
- 2010-08-20 CN CN201510564915.XA patent/CN105331633A/zh active Pending
- 2010-08-20 CA CA2771540A patent/CA2771540C/en active Active
- 2010-08-20 PT PT162045389T patent/PT3210622T/pt unknown
- 2010-08-20 EP EP10747133.6A patent/EP2467158B1/en active Active
-
2012
- 2012-02-20 ZA ZA2012/01245A patent/ZA201201245B/en unknown
- 2012-02-21 CL CL2012000447A patent/CL2012000447A1/es unknown
- 2012-03-20 CO CO12046741A patent/CO6511253A2/es unknown
-
2015
- 2015-08-04 CL CL2015002175A patent/CL2015002175A1/es unknown
- 2015-12-17 JP JP2015246684A patent/JP2016041079A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012002114A (es) | Vacuna de paramixovirus aviar recombinante y metodo para hacerla y usarla. | |
| Qu et al. | Circular RNA vaccines against SARS-CoV-2 and emerging variants | |
| Ghattas et al. | Vaccine technologies and platforms for infectious diseases: current progress, challenges, and opportunities | |
| WO2011031424A3 (en) | High shear system and method for the production of acids | |
| Zhang et al. | A thermostable mRNA vaccine against COVID-19 | |
| Wang et al. | Hemagglutinin-esterase-fusion (HEF) protein of influenza C virus | |
| Bouazzaoui et al. | Strategies for vaccination: conventional vaccine approaches versus new-generation strategies in combination with adjuvants | |
| Rauch et al. | New vaccine technologies to combat outbreak situations | |
| Lundstrom | Replicon RNA viral vectors as vaccines | |
| Loomis et al. | Chimeric fusion (F) and attachment (G) glycoprotein antigen delivery by mRNA as a candidate Nipah vaccine | |
| Hekele et al. | Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice | |
| CA2525953C (en) | High titer recombinant influenza viruses for vaccines and gene therapy | |
| JP2023082121A (ja) | Ｒｎａの投与のための配合物 | |
| JP2015522581A5 (enExample) | ||
| Márquez-Jurado et al. | An alanine-to-valine substitution in the residue 175 of Zika virus NS2A protein affects viral RNA synthesis and attenuates the virus in vivo | |
| CN107190022B (zh) | 一种快速构建禽传染性支气管炎病毒反向遗传株的方法 | |
| NO20080358L (no) | Fremgangsmater og sammensetninger for a fremstille negative-sense virus RNA i hundedyrceller | |
| BR112012025364A2 (pt) | método para geração de partícula semelhante a vírus de parvovírus b19 | |
| JP2013537518A5 (enExample) | ||
| BRPI1015053A2 (pt) | partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina | |
| RS62864B1 (sr) | Rnk replikon za univerzalnu i efikasnu ekspresiju gena | |
| JP2012511579A5 (enExample) | ||
| JP2010530245A5 (enExample) | ||
| Zhang et al. | CRISPR/Cas9 Delivery Mediated with Hydroxyl‐Rich Nanosystems for Gene Editing in Aorta | |
| WO2007124327A3 (en) | Methods and compositions for expressing negative-sense viral rna in canine cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |